Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018
Eloisa de Sá Moreira,1 David Robinson,2 Stephanie Hawthorne,2 Linda Zhao,2 Madelyn Hanson,2 Gena Kanas,2 Matthew Turnure,2 Christine Davis,2 Otavio Clark2 1Health Division, Kantar, São Paulo, Brazil; 2Health Division, Kantar, New York, NY, USACorrespondence: Matthew TurnureKantar 175 Greenwich St, W...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-12-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patterns-of-care-and-outcomes-for-non-metastatic-prostate-cancer-in-th-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1818572632135565312 |
|---|---|
| author | de Sá Moreira E Robinson D Hawthorne S Zhao L Hanson M Kanas G Turnure M Davis C Clark O |
| author_facet | de Sá Moreira E Robinson D Hawthorne S Zhao L Hanson M Kanas G Turnure M Davis C Clark O |
| author_sort | de Sá Moreira E |
| collection | DOAJ |
| description | Eloisa de Sá Moreira,1 David Robinson,2 Stephanie Hawthorne,2 Linda Zhao,2 Madelyn Hanson,2 Gena Kanas,2 Matthew Turnure,2 Christine Davis,2 Otavio Clark2 1Health Division, Kantar, São Paulo, Brazil; 2Health Division, Kantar, New York, NY, USACorrespondence: Matthew TurnureKantar 175 Greenwich St, WTC 3, 35th Floor, New York, NY, 10007, USATel +1 314-221-4323Email matthew.turnure@Kantar.comPurpose: We describe patterns of care and treatment outcomes for non-metastatic PCa (nmPCA), either hormone-sensitive or castration-resistant, in the United States of America (USA) in 2018.Methods: A survey (CancerMPact®) recruited physicians nationwide to answer an online questionnaire about how they treated patients with nmPCA. Questions covered aspects of treatment at all disease stages. Board-certified urologists and oncologists with at least five years of clinical practice and who treated at least 30 PCa patients monthly were included.Results: The survey included responses from ninety-four physicians with an average of 17.5 years of clinical practice, who had treated a combined average of 4415 patients with nmPCA per month in 2018. Approximately 40% of patients in stage I were managed with either active surveillance or observation/no therapy, decreasing to 20%, 8% and 6% in stages II, III and IV(M0), respectively. Intensity-modulated radiotherapy was favored over other radiotherapy modalities, with rates of use ranging between 60% and 69% depending on disease stage. Leuprolide as monotherapy or in combination with enzalutamide, abiraterone or bicalutamide were the most common systemic treatment options for non-metastatic hormone-sensitive PCa (nmHSPC) patients with the first or second recurrence. Only 16.5% of non-metastatic castration-resistant PCa (nmCRPC) patients did not relapse within five years of initial therapy for nmCRPC.Conclusion: While PCa treatment recommendations are rapidly changing due to advances in treatment, we observed great concordance between their most current versions and real-world data treatment patterns reported by US physicians.Keywords: real-world evidence, treatment, physician reported, questionnaire |
| first_indexed | 2024-12-15T00:00:12Z |
| format | Article |
| id | doaj.art-2109aa9034ea4535ab1dc4621cd3e0c1 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-15T00:00:12Z |
| publishDate | 2021-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-2109aa9034ea4535ab1dc4621cd3e0c12022-12-21T22:42:57ZengDove Medical PressCancer Management and Research1179-13222021-12-01Volume 139127913771378Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018de Sá Moreira ERobinson DHawthorne SZhao LHanson MKanas GTurnure MDavis CClark OEloisa de Sá Moreira,1 David Robinson,2 Stephanie Hawthorne,2 Linda Zhao,2 Madelyn Hanson,2 Gena Kanas,2 Matthew Turnure,2 Christine Davis,2 Otavio Clark2 1Health Division, Kantar, São Paulo, Brazil; 2Health Division, Kantar, New York, NY, USACorrespondence: Matthew TurnureKantar 175 Greenwich St, WTC 3, 35th Floor, New York, NY, 10007, USATel +1 314-221-4323Email matthew.turnure@Kantar.comPurpose: We describe patterns of care and treatment outcomes for non-metastatic PCa (nmPCA), either hormone-sensitive or castration-resistant, in the United States of America (USA) in 2018.Methods: A survey (CancerMPact®) recruited physicians nationwide to answer an online questionnaire about how they treated patients with nmPCA. Questions covered aspects of treatment at all disease stages. Board-certified urologists and oncologists with at least five years of clinical practice and who treated at least 30 PCa patients monthly were included.Results: The survey included responses from ninety-four physicians with an average of 17.5 years of clinical practice, who had treated a combined average of 4415 patients with nmPCA per month in 2018. Approximately 40% of patients in stage I were managed with either active surveillance or observation/no therapy, decreasing to 20%, 8% and 6% in stages II, III and IV(M0), respectively. Intensity-modulated radiotherapy was favored over other radiotherapy modalities, with rates of use ranging between 60% and 69% depending on disease stage. Leuprolide as monotherapy or in combination with enzalutamide, abiraterone or bicalutamide were the most common systemic treatment options for non-metastatic hormone-sensitive PCa (nmHSPC) patients with the first or second recurrence. Only 16.5% of non-metastatic castration-resistant PCa (nmCRPC) patients did not relapse within five years of initial therapy for nmCRPC.Conclusion: While PCa treatment recommendations are rapidly changing due to advances in treatment, we observed great concordance between their most current versions and real-world data treatment patterns reported by US physicians.Keywords: real-world evidence, treatment, physician reported, questionnairehttps://www.dovepress.com/patterns-of-care-and-outcomes-for-non-metastatic-prostate-cancer-in-th-peer-reviewed-fulltext-article-CMARreal-world evidencetreatmentphysician reportedquestionnaire |
| spellingShingle | de Sá Moreira E Robinson D Hawthorne S Zhao L Hanson M Kanas G Turnure M Davis C Clark O Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 Cancer Management and Research real-world evidence treatment physician reported questionnaire |
| title | Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 |
| title_full | Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 |
| title_fullStr | Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 |
| title_full_unstemmed | Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 |
| title_short | Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018 |
| title_sort | patterns of care and outcomes for non metastatic prostate cancer in the united states results of the cancermpact reg survey 2018 |
| topic | real-world evidence treatment physician reported questionnaire |
| url | https://www.dovepress.com/patterns-of-care-and-outcomes-for-non-metastatic-prostate-cancer-in-th-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT desamoreirae patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT robinsond patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT hawthornes patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT zhaol patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT hansonm patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT kanasg patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT turnurem patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT davisc patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 AT clarko patternsofcareandoutcomesfornonmetastaticprostatecancerintheunitedstatesresultsofthecancermpactregsurvey2018 |